Leukocytapheresis for the treatment of active pouchitis: a pilot study

被引：10

作者：

Araki, Yasumi ^{[2
]}

Mitsuyama, Keiichi ^{[1
]}

Nagae, Takaaki ^{[2
]}

Tou, Yuji ^{[2
]}

Nakagawa, Motonori ^{[2
]}

Iwatani, Yasue ^{[2
]}

Harada, Masakazu ^{[2
]}

Ozasa, Hiroyuki ^{[2
]}

Sata, Michio ^{[1
]}

Noake, Toshihiro ^{[2
]}

机构：

[1] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Kurume, Fukuoka 8300011, Japan

[2] Kurume Coloproctol Ctr, Kurume, Fukuoka, Japan

来源：

JOURNAL OF GASTROENTEROLOGY | 2008年 / 43卷 / 07期

关键词：

ileal pouch-anal anastomosis; leukocytapheresis; pouchitis; ulcerative colitis;

D O I：

10.1007/s00535-008-2199-0

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background. Pouchitis is a major long-term complication of ileal pouch-anal anastomosis for ulcerative colitis. The aim of this study is to investigate the efficacy of leukocytapheresis for the treatment of active pouchitis. Methods. Eight patients with active pouchitis received leukocytapheresis weekly for 5 weeks in an open-label treatment protocol together with baseline therapy. Results. Patients showed significant improvement in their pouchitis disease activity index scores, from 9.5 (range, 8-10) to 4.0 (range, 2-8) (P < 0.05). Six (75%) of the 8 treated patients achieved remission. No adverse events were observed. Conclusions. Leukocytapheresis therapy could be a new therapeutic strategy for patients with pouchitis after ileal pouch-anal anastomosis for ulcerative colitis. These encouraging results lead us to propose a randomized controlled trial.

引用

页码：571 / 575

页数：5

共 30 条

[11] The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease [J].

Kanai, Takanori ;

Hibi, Toshifumi ;

Watanabe, Mamoru .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (05) :453-466

[12] Activation of signal-transducer and activator of transcription 1 (STAT1) in pouchitis [J].

Kühbacher, T ;

Gionchetti, P ;

Hampe, J ;

Helwig, U ;

Rosenstiel, P ;

Campieri, M ;

Buhr, HJ ;

Schreiber, S .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (03) :395-401

[13]

Meagher AP, 1998, BRIT J SURG, V85, P800

[14] Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis [J].

Mimura, T ;

Rizzello, F ;

Helwig, U ;

Poggioli, G ;

Schreiber, S ;

Talbot, IC ;

Nicholls, RJ ;

Gionchetti, P ;

Campieri, M ;

Kamm, MA .

GUT, 2004, 53 (01) :108-114

[15] Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis [J].

Mimura, T ;

Rizzello, F ;

Helwig, U ;

Poggioli, G ;

Schreiber, S ;

Talbot, IC ;

Nicholls, RJ ;

Gionchetti, P ;

Campieri, M ;

Kamm, MA .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (05) :909-917

[16] An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis [J].

Miner, P ;

Wedel, M ;

Bane, B ;

Bradley, J .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (03) :281-286

[17] Diminished cytokine signalling against bacterial components in mononuclear leucocytes from ulcerative colitis patients after leukocytapheresis [J].

Mitsuyama, K ;

Suzuki, A ;

Matsumoto, S ;

Tomiyasu, N ;

Takaki, K ;

Takedatsu, H ;

Masuda, J ;

Handa, K ;

Harada, K ;

Nishida, H ;

Toyonaga, A ;

Sata, M .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 141 (01) :130-140

[18] Systematic review: the management of pouchitis [J].

Pardi, DS ;

Sandborn, WJ .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (08) :1087-1096

[19] CYTOKINE PRODUCTION IN POUCHITIS IS SIMILAR TO THAT IN ULCERATIVE-COLITIS [J].

PATEL, RT ;

BAIN, I ;

YOUNGS, D ;

KEIGHLEY, MRB .

DISEASES OF THE COLON & RECTUM, 1995, 38 (08) :831-837

[20] POUCHITIS AFTER ILEAL POUCH-ANAL ANASTOMOSIS - A POUCHITIS DISEASE-ACTIVITY INDEX [J].

SANDBORN, WJ ;

TREMAINE, WJ ;

BATTS, KP ;

PEMBERTON, JH ;

PHILLIPS, SF .

MAYO CLINIC PROCEEDINGS, 1994, 69 (05) :409-415

← 1 2 3 →